Introduction. Primary referral for infectious and inflammatory diseases of the pharynx reaches 30%.Aim. To study the effectiveness of ambazon in patients with acute tonsillopharyngitis.Materials and methods. The study was conducted at the SCDC Clinics of the Samara State Medical University and the CDC “Persona-Med” LLC in 75 patients (45.9 ± 11.2 years old) with acute tonsillopharyngitis (ATP). The main group (Group I, n = 48) additionally received ambazon, 1 tablet for resorption 15 minutes after meals 4 times a day for 4 days. The control group (Group II, n = 27) received symptomatic therapy. On the 1st, 2nd and 4th day, the complaint of sore throat was assessed using a visual analogue scale (VAS), the frequency of additional complaints, and the pharyngoscopic picture using a 4-point scale.Results and discussion. On the 2nd day, the severity of sore throat according to VAS in group I was 3.5 ± 0.2 points, in group II 4.9 ± 0.3 points (p < 0.05). On the 4th day, the severity of sore throat in group I had lower values 1.1 ± 0.1 points, in group II 2.9 ± 0.1 points (p < 0.05). On the 2nd day, complaints of a sensation of a foreign body in the oropharynx and discomfort when swallowing in group I amounted to 27.1% and 45.8%, and in group II 77.8% and 66.7%, respectively. The pharyngoscopic picture in group I was characterized by a decrease in the severity of edema and hyperemia of the pharyngeal mucosa (score of 1.3 ± 0.3 points and 1.1 ± 0.2 points), in group II 2.1 ± 0.3 points and 2.9 ± 0.4 points, respectively. On the 4th day, the pharyngoscopic picture in group I returned to normal, while in group II, hyperemia and edema of the mucosa and an increase in regional lymph nodes persisted.Conclusions. The use of ambazon in the treatment of ATP allows to reduce the severity of the pain symptom, reduce the frequency of additional complaints and normalize the pharyngoscopic picture.